Discussion: reported that mutations at position 68 followed the initial selection for K65R and M184 V mutations.
High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy.
Discussion: M184 V also increases susceptibility to Zidovudine, Stavudine, and Tenofovir, and is associated with a clinically significant reduction in HIV-1 replication in vivo.
Discussion: Due to the decrease in susceptibility, patients infected with HIV-1 with the M184 V mutation continue treatment with Lamivudine, resulting in continuous exposure, and consequently, higher frequency of the mutation.
Discussion: Supplementary Digital Content 3) has been shown previously.M184 V mutation causes high-level resistance to Lamivudine, and therefore the high frequency of the mutation observed in this study is not unusual since the drug is the most common NRTI in use in Ghana.
Discussion: The predominance of M184 V and D67N among mutations associated with resistance to
Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
PMID: 32065630
2020
The Journal of antimicrobial chemotherapy
Abstract: BACKGROUND: M184V/I NRTI resistance mutations can be selected by either lamivudine/emtricitabine or abacavir.
Abstract: CONCLUSIONS: M184V/I as a unique NRTI resistance mutation, regardless of possible selection by regimens containing lamivudine/emtricitabine or abacavir, does not affect the virological response of well-controlled patients who switched to abacavir/lamivudine/dolutegravir for at least 12 months.
Abstract: OBJECTIVES: We assessed the efficacy of abacavir/lamivudine/dolutegravir when used in HIV-infected pretreated patients with an undetectable VL who previously harboured M184V/I as a unique NRTI resistance mutation in a genotypic resistance test and had no resistance to
Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.
Abstract: Additionally, we experimentally simulated previously reported ETV/3TC resistance for HBV using HIVY115F/F116Y/Q151M with F160M/M184V (L180M/M204V in HBV RT) substituted.
Abstract: Structural analysis of RTY115F/F116Y/Q151M/F160M/M184V:DNA:3TC-TP also demonstrated that the loosely bound 3TC-TP is misaligned at the active site to prevent a steric clash with the side chain gamma-methyl of Val184.
Introduction: 3TC is also approved as an anti-HIV-1 agent, and M184V in HIV-1 RT, which co
Natural polymorphisms in HIV-1 CRF01_AE strain and profile of acquired drug resistance mutations in a long-term combination treatment cohort in northeastern China.
Result: Result: Nine known DRMs (K65R, V106 M, Y115F, V179 T/E/D, Y181C, M184 V, and G190S) and two potential new DRMs (V75 L and L228R) were demonstrated to be under positive selection pressure (Ka/Ks > 1, LOD > 2).
Result: The NRTI-associated DRMs detected at TF time point in descending order included K65R (57.1%), M184 V/I (47.6%), S68G (26.2%), A62V (14.3%), K70E/R (9.5%), and Y115F (9.5%).
Synthesis and biological evaluation of a series of 2-(((5-akly/aryl-1H-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimi din-4(3H)-ones as potential HIV-1 inhibitors.
Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia.
Abstract: The mutation M184V which confers resistance to NRTI drugs of lamivudine (3TC) and emtricitabine (FTC) was the most common (81%) among NRTI associated mutations followed by K65R (34.5%) which is associated with both tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide fumarate (TAF) resistance.
Method: The typical drugs that were available in public health facilities offering third line ART at the time of the study included the NNRTI etravarine (rilpivarine and doravarine were not yet available) and the NRTIs lamivudine and emtricitabine (for M184V mutations).
Result: Overall, the 10 most common mutations were M184V (81%)
Table: M184V
Prevalence of acquired drug resistance mutations in antiretroviral- experiencing subjects from 2012 to 2017 in Hunan Province of central South China.
Abstract: M184V (62.04%), K103N (41.90%) and I54L (3.83%) were the most common observed mutations, respectively, in NRTI-, NNRTI- and PI-associated drug resistance.
Result: The most common primary NRTI mutations detected included M184V (62.04%), K65R (20.24%), K70R (15.01%), T215D/S (9.41%), Y115F (7.22%) and M41L (6.35%).
Table: M184V/I
Discussion: Although M184V/I causes high-level in vitro resistance to 3TC, PMID: 33844760
2020
Revista medica de Chile
Abstract: The mutations in reverse transcriptase were M41L, L210W, D67N, K70E, M184V, K103N (6.36%, 95% CI 3.5-10.4), G190A, E138A, K101E, and I84V in protease.
Use of a mutation-specific genotyping method to assess for HIV-1 drug resistance in antiretroviral-naive HIV-1 Subtype C-infected patients in Botswana.
Discussion: Another limitation in this study was the lack of samples with M184V and V106M, making it difficult to draw a conclusion on the performance of PANDAA in detecting V106M and M184V.
Discussion: By using PANDAA, we targeted the most likely mutations to develop to these medications in HIV-1 subtype C, the M184V, K103N and V106M mutations in reverse transcriptase, a targeted and cost-effective approach to genotyping is possible .
Discussion: Firstly, we only examined the most common relevant resistant mutations, V106M, K103N and M184V of the reverse transcriptase<
HIV mutation literature information.
PMID: 
2020
BMC infectious diseases
Browser Board
Co-occurred Entities
Filtrator
ViMRT